Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Pfizer : delays drug price hikes after talking with Trump

share with twitter share with LinkedIn share with facebook
share via e-mail
07/11/2018 | 03:20am CEST
The Pfizer logo is seen at their world headquarters in Manhattan, New York, U.S.

WASHINGTON/NEW YORK (Reuters) - Pfizer Inc said on Tuesday it was deferring drug price increases for no more than six months after the company's chief executive officer had an extensive conversation with U.S. President Donald Trump.

The rollback came a day after Trump took aim at Pfizer and other U.S. drugmakers for raising prices on some of their medicines, saying in a tweet that they "should be ashamed" and that his administration would respond.

Pfizer on Tuesday said it would defer price increases that went into effect on July 1 until the end of the year or until the president's drug pricing blueprint goes into effect - whichever is sooner. The company said it would return drug prices to their pre-July 1 levels as soon as technically possible.

On Tuesday, Trump said in a tweet that Pfizer had agreed to roll back drug price hikes after he and U.S. Health and Human Services Secretary Alex Azar spoke with the company's CEO, Ian Read.

"We applaud Pfizer for this decision and hope other companies do the same," Trump, who is traveling in Europe, said in a tweet.

Pfizer, one of the largest pharmaceutical companies, now likely will not raise drug prices until after the 2018 midterm elections in November. That gives Trump, who made lowering prescription drug prices a top 2016 presidential campaign issue, a short-term victory he can point to in the run-up to the elections, which are being closely watched to see if Trump's fellow Republicans will be able to maintain control of both the Senate and the House of Representatives.

Pfizer raised list prices on around 40 medicines earlier this month. Those include Viagra, cholesterol drug Lipitor and arthritis treatment Xeljanz, according to Wells Fargo. List prices do not include rebates and discounts drugmakers may offer.

The Trump administration has not yet taken significant action to lower drug prices. Azar has said lowering prices long term will take years because of the complexity of the healthcare system.

Trump rolled out a blueprint in May on how his administration planned to lower drug prices. Trump said in May that some drug companies would announce "voluntary, massive" price decreases in two weeks, though none have materialized yet.

Pharmaceutical company shares rose after Trump unveiled his drug pricing blueprint.

Azar praised Pfizer on Tuesday. "I commend Pfizer for its constructive and professional approach, and its desire to work with President Trump to be part of the solution and not part of the problem," he said in a statement.

(Reporting by Yasmeen Abutaleb and Michael Erman; Additional reporting by Eric Walsh; Editing by Lisa Shumaker and Leslie Adler)

By Yasmeen Abutaleb and Michael Erman

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on PFIZER
07/18Novartis hints at 2018 outlook hike despite drug price freeze
07/18Novartis hints at 2018 outlook hike despite drug price freeze
07/18PFIZER : Lilly pain drug meets late-stage trial goals
07/18Pfizer, Lilly See Positive Top-Line Results From Phase 3 Trial of Tanezumab
07/18PFIZER : Sen. Murray Criticizes Trump Administration for Failing to Lower Drug P..
07/18PFIZER : ACRES Unveils Global Quality Standard for Clinical Research Site Accred..
07/18SPARK THERAPEUTICS : Pfizer enters late-stage haemophilia B gene therapy trial
07/17ASTELLAS PHARMA : U.S. FDA Approves XTANDI for the Treatment of Men with Non-Met..
07/17SEN. BALDWIN TO PFIZER CEO : Make Drug Price Reductions Permanent
07/17PFIZER : Biotech Stocks Continue Uptrend
More news
News from SeekingAlpha
07/18ARBUTUS BIOPHARMA : Long-Term Growth Prospect Flying Too Close To The Sun 
07/18Why Johnson & Johnson Is An Attractive Investment 
07/18FDA committed to easing approval path for biosimilars 
07/18Google Faces Record $5 Billion Fine Over Android (Wall Street Breakfast Podca.. 
07/18Pfizer and Lilly's tanezumab successful in late-stage osteoarthritis pain stu.. 
Financials ($)
Sales 2018 54 353 M
EBIT 2018 20 784 M
Net income 2018 13 077 M
Debt 2018 21 973 M
Yield 2018 3,63%
P/E ratio 2018 17,33
P/E ratio 2019 15,72
EV / Sales 2018 4,46x
EV / Sales 2019 4,25x
Capitalization 220 B
Duration : Period :
Pfizer Technical Analysis Chart | PFE | US7170811035 | 4-Traders
Technical analysis trends PFIZER
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 39,8 $
Spread / Average Target 5,7%
EPS Revisions
Ian C. Read Chairman & Chief Executive Officer
Albert Bourla Chief Operating Officer & Director
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER3.20%220 236
JOHNSON & JOHNSON-10.76%346 292
ROCHE HOLDING LTD.-5.88%200 995
NOVARTIS-5.10%200 139
MERCK AND COMPANY11.12%168 225
AMGEN12.06%128 318